利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

91 条记录 (耗时 0.021 秒)

    Crystalline forms of carvedilol and processes for their preparation
    4.
    发明申请
    Crystalline forms of carvedilol and processes for their preparation 审中-公开
    卡维地洛的结晶形式及其制备方法

    公开(公告)号：US20070043099A1

    公开(公告)日：2007-02-22

    申请号：US11450699

    申请日：2006-06-09

    申请人： Igor Lifshitz ,  Shlomit Wizel

    发明人： Igor Lifshitz ,  Shlomit Wizel

    IPC分类号： A61K31/403 ,  C07D209/82

    CPC分类号： C07D209/88

    摘要： This invention relates to a novel crystalline form of carvedilol, to processes for its preparation, to compositions containing it and to its use in medicine. This invention further relates to a novel process for preparing crystalline carvedilol Form II.

    摘要翻译： 本发明涉及一种新颖的卡维地洛结晶形式，其制备方法，含有它的组合物及其在药物中的用途。 本发明还涉及制备结晶卡维地洛II型的新方法。

    Crystalline rosuvastatin calcium and compositions thereof for treatment of hyperlipidaemia
    6.
    发明授权
    Crystalline rosuvastatin calcium and compositions thereof for treatment of hyperlipidaemia 失效
    结晶罗苏伐他汀钙及其组合物用于治疗高脂血症

    公开(公告)号：US07994178B2

    公开(公告)日：2011-08-09

    申请号：US11901813

    申请日：2007-09-18

    申请人： Shlomit Wizel ,  Valerie Niddam-Hildesheim ,  Shalom Shabat

    发明人： Shlomit Wizel ,  Valerie Niddam-Hildesheim ,  Shalom Shabat

    IPC分类号： A61K31/4965

    CPC分类号： C07D239/42

    摘要： The present invention provides a crystalline form of rosuvastatin calcium characterized by an X-ray powder diffraction pattern having peaks at about 4.7, 19.4 and 22.3° 2θ±0.2° 2θ. The crystalline form of the invention may be further characterized by a DSC thermogram with an endotherm at about 132° C. and another broad endotherm at about 220° C. to about 240° C., and a TGA thermogram showing a weight loss of about of 3 to about 5 percent up to about 100° C. The invention also provides a pharmaceutical composition comprising the crystalline rosuvastatin calcium, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.

    摘要翻译： 本发明提供了一种结晶形式的瑞舒伐他汀钙，其特征在于X-射线粉末衍射图在约4.7,19​​.4和22.3±2之间具有峰;±0.2°2。 本发明的结晶形式可以进一步表征为具有在约132℃的吸热和约220℃至约240℃的吸热的另一广泛吸热的DSC热分析图，显示出约3至 约5％至约100℃。本发明还提供了包含结晶罗苏伐他汀钙或其药学上可接受的盐和至少一种药学上可接受的赋形剂的药物组合物。

    POLYMORPHS OF FEXOFENADINE HYDROCHLORIDE
    8.
    发明申请
    POLYMORPHS OF FEXOFENADINE HYDROCHLORIDE 审中-公开
    FEXOFENADINE HYDROCHLORIDE的聚合物

    公开(公告)号：US20090012121A1

    公开(公告)日：2009-01-08

    申请号：US12207399

    申请日：2008-09-09

    申请人： Ben-Zion DOLITZKY ,  Shlomit Wizel ,  Barnaba Krochmal ,  Dov Diller ,  Irwin Gross

    发明人： Ben-Zion DOLITZKY ,  Shlomit Wizel ,  Barnaba Krochmal ,  Dov Diller ,  Irwin Gross

    IPC分类号： A61K31/445 ,  C07D211/34

    CPC分类号： C07D211/22

    摘要： The present invention provides novel crystal forms of fexofenadine hydrochloride Forms V, VI and VIII through XV and processes for their preparation and preparation of amorphous form and other crystalline forms of fexofenadine hydrochloride. Forms XIV and XV are solvates of ethyl acetate, while Form IX is a solvate of MTBE or cyclohexane. The forms are useful for administration to humans and animals to alleviate symptoms caused by histamine. The present invention further provides pharmaceutical compositions of the new crystalline forms.

    摘要翻译： 本发明提供盐酸非索非那定形式V，VI和VIII至XV的新型结晶形式及其制备和制备盐酸非索非那定的无定形形式和其它结晶形式的方法。 形式XIV和XV是乙酸乙酯的溶剂合物，而形式IX是MTBE或环己烷的溶剂合物。 这些形式可用于给予人类和动物以减轻组胺引起的症状。 本发明还提供了新的结晶形式的药物组合物。